Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1215867-40-5

(S)-2′-amino-3-(p-tolyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-7-yl trifluoromethanesulfonate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1215867-40-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1215867-40-5 Structure

  • Basic information

    1. Product Name: (S)-2′-amino-3-(p-tolyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-7-yl trifluoromethanesulfonate
    2. Synonyms: (S)-2′-amino-3-(p-tolyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-7-yl trifluoromethanesulfonate
    3. CAS NO:1215867-40-5
    4. Molecular Formula:
    5. Molecular Weight: 491.447
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1215867-40-5.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: (S)-2′-amino-3-(p-tolyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-7-yl trifluoromethanesulfonate(CAS DataBase Reference)
    10. NIST Chemistry Reference: (S)-2′-amino-3-(p-tolyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-7-yl trifluoromethanesulfonate(1215867-40-5)
    11. EPA Substance Registry System: (S)-2′-amino-3-(p-tolyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-7-yl trifluoromethanesulfonate(1215867-40-5)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1215867-40-5(Hazardous Substances Data)

1215867-40-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1215867-40-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,5,8,6 and 7 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1215867-40:
(9*1)+(8*2)+(7*1)+(6*5)+(5*8)+(4*6)+(3*7)+(2*4)+(1*0)=155
155 % 10 = 5
So 1215867-40-5 is a valid CAS Registry Number.

1215867-40-5Relevant articles and documents

Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): Identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′ H -spiro[chromeno[2,3- b ]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)

Dineen, Thomas A.,Chen, Kui,Cheng, Alan C.,Derakhchan, Katayoun,Epstein, Oleg,Esmay, Joel,Hickman, Dean,Kreiman, Chuck E.,Marx, Isaac E.,Wahl, Robert C.,Wen, Paul H.,Weiss, Matthew M.,Whittington, Douglas A.,Wood, Stephen,Fremeau, Robert T.,White, Ryan D.,Patel, Vinod F.

, p. 9811 - 9831 (2015/02/05)

We have previously shown that the aminooxazoline xanthene scaffold can generate potent and orally efficacious BACE1 inhibitors although certain of these compounds exhibited potential hERG liabilities. In this article, we describe 4-aza substitution on the xanthene core as a means to increase BACE1 potency while reducing hERG binding affinity. Further optimization of the P3 and P2′ side chains resulted in the identification of 42 (AMG-8718), a compound with a balanced profile of BACE1 potency, hERG binding affinity, and Pgp recognition. This compound produced robust and sustained reductions of CSF and brain Aβ levels in a rat pharmacodynamic model and exhibited significantly reduced potential for QTc elongation in a cardiovascular safety model.

SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS

-

, (2011/10/10)

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula (I) wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1215867-40-5